Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test the feasibility and acceptability of an adapted psychosocial intervention, called Emotion and Symptom-focused Engagement for Caregivers (EASE-CG), to reduce traumatic stress symptoms and other psychological distress and increase well-being in primary caregivers of patients newly diagnosed with acute leukemia.


Clinical Trial Description

Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) is a brief psychotherapeutic intervention designed for primary caregivers of patients newly diagnosed with acute leukemia (AL). The EASE-CG intervention was adapted from a previous psychotherapeutic intervention for adult patients newly diagnosed with AL, called Emotion and Symptom-focused Engagement (EASE). In a previous pilot trial, EASE was associated with reductions in traumatic stress and physical symptom burden in adult patients with AL. EASE-CG is a sub-study of a multi-center, longitudinal, mixed-methods study on the experience of traumatic stress in primary caregivers of patients newly diagnosed with AL within three months of admission to the hospital (Main study). The purpose of this sub-study is to conduct a non-randomized, mixed-methods pilot study to test the feasibility and acceptability of EASE-CG. A subset of caregivers of pediatric patients from the Main study will be approached to participate in EASE-CG. Quantitative measures will be administered at baseline, 1, 3 (primary endpoint), 6, 9, and 12 months (Main study endpoint). Participants may be invited to brief, semi-structured interviews. The study will take place at the Hospital for Sick Children; the largest leukemia treatment center in Canada for pediatric patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05236296
Study type Interventional
Source University Health Network, Toronto
Contact Ally Yu
Phone 416-813-7654
Email ally.yu@uhnresearch.ca
Status Recruiting
Phase N/A
Start date April 12, 2022
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03680677 - Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Completed NCT04194086 - Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia Phase 1/Phase 2
Completed NCT04710212 - Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
Terminated NCT01050764 - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Phase 1/Phase 2
Completed NCT03434704 - Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole Phase 2
Recruiting NCT05823571 - Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Phase 1
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Completed NCT04745416 - Clinical Characteristics of Patients With Leukemia and COVID-19
Not yet recruiting NCT03336632 - Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT Phase 2
Completed NCT05969600 - The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3
Recruiting NCT06335277 - Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
Recruiting NCT03553238 - Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL Phase 2/Phase 3
Recruiting NCT03564704 - Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Phase 2/Phase 3
Recruiting NCT03564470 - Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL Phase 2/Phase 3
Terminated NCT03963024 - Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT Phase 1
Completed NCT04051216 - The SMART CART Study: Health Information Technology N/A
Completed NCT03297476 - Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk Leukemia
Recruiting NCT04482894 - Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS Phase 2